메뉴 건너뛰기




Volumn 53, Issue 2, 2013, Pages 158-183

Diretrizes para o tratamento da artrite reumatoide guidelines for the drug treatment of rheumatoid arthritis

Author keywords

[No Author keywords available]

Indexed keywords


EID: 84883213886     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0482-50042013000200004     Document Type: Article
Times cited : (9)

References (210)
  • 1
    • 33750615070 scopus 로고    scopus 로고
    • Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review
    • Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36:182-8.
    • (2006) Semin Arthritis Rheum. , vol.36 , pp. 182-188
    • Alamanos, Y.1    Voulgari, P.V.2    Drosos, A.A.3
  • 3
    • 11344253906 scopus 로고    scopus 로고
    • A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up
    • Verstappen SM, van Albada-Kuipers GA, Bijlsma JW, Blaauw AA, Schenk Y, Haanen HC, et al. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis. 2005;64:38-43.
    • (2005) Ann Rheum Dis. , vol.64 , pp. 38-43
    • Verstappen, S.M.1    van Albada-Kuipers, G.A.2    Bijlsma, J.W.3    Blaauw, A.A.4    Schenk, Y.5    Haanen, H.C.6
  • 5
    • 79958091017 scopus 로고    scopus 로고
    • 2011 Consensus of the Brazilian Society of Rheumatology for diagnosis and early assessment of rheumatoid arthritis
    • Mota LM, Cruz BA, Brenol CV, Pereira IA, Fronza LS, Bertolo MB, et al. 2011 Consensus of the Brazilian Society of Rheumatology for diagnosis and early assessment of rheumatoid arthritis. Rev Bras Reumatol. 2011;51:199-219.
    • (2011) Rev Bras Reumatol. , vol.51 , pp. 199-219
    • Mota, L.M.1    Cruz, B.A.2    Brenol, C.V.3    Pereira, I.A.4    Fronza, L.S.5    Bertolo, M.B.6
  • 7
    • 78149492075 scopus 로고    scopus 로고
    • State-of-the-art: rheumatoid arthritis
    • McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis. 2010;69:1898-906.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 1898-1906
    • McInnes, I.B.1    O'Dell, J.R.2
  • 11
    • 36249020956 scopus 로고    scopus 로고
    • Effects of an educational-behavioral joint protection program on people with moderate to severe rheumatoid arthritis: a randomized controlled trial
    • Masiero S, Boniolo A, Wassermann L, Machiedo H, Volante D, Punzi L. Effects of an educational-behavioral joint protection program on people with moderate to severe rheumatoid arthritis: a randomized controlled trial. Clin Rheumatol. 2007;26:2043-50.
    • (2007) Clin Rheumatol. , vol.26 , pp. 2043-2050
    • Masiero, S.1    Boniolo, A.2    Wassermann, L.3    Machiedo, H.4    Volante, D.5    Punzi, L.6
  • 13
    • 44149106595 scopus 로고    scopus 로고
    • CyclooArtrite xygenase-2 selective nonsteroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation
    • Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. CyclooArtrite xygenase-2 selective nonsteroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12:1-278.
    • (2008) Health Technol Assess. , vol.12 , pp. 1-278
    • Chen, Y.F.1    Jobanputra, P.2    Barton, P.3    Bryan, S.4    Fry-Smith, A.5    Harris, G.6
  • 14
    • 0036140321 scopus 로고    scopus 로고
    • Low-dose prednisone therapy for patients with early rheumatoid arthritis:clinical efficacy, disease-modifying properties,and side effects:a randomized,double-blind, placebo-controlled clinical trial
    • van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early rheumatoid arthritis:clinical efficacy, disease-modifying properties,and side effects:a randomized,double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136:1-12.
    • (2002) Ann Intern Med. , vol.136 , pp. 1-12
    • van Everdingen, A.A.1    Jacobs, J.W.2    Siewertsz Van Reesema, D.R.3    Bijlsma, J.W.4
  • 15
    • 9244247260 scopus 로고    scopus 로고
    • Treatment of rheumatoidarthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
    • O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoidarthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996;334:1287-91.
    • (1996) N Engl J Med. , vol.334 , pp. 1287-1291
    • O'Dell, J.R.1    Haire, C.E.2    Erikson, N.3    Drymalski, W.4    Palmer, W.5    Eckhoff, P.J.6
  • 16
    • 0023924884 scopus 로고
    • A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis
    • Williams HJ, Ward JR, Dahl SL, Clegg DO, Willkens RF, Oglesby T, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum. 1988;31:702-13.
    • (1988) Arthritis Rheum. , vol.31 , pp. 702-713
    • Williams, H.J.1    Ward, J.R.2    Dahl, S.L.3    Clegg, D.O.4    Willkens, R.F.5    Oglesby, T.6
  • 17
    • 0030751946 scopus 로고    scopus 로고
    • Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
    • Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350:309-18.
    • (1997) Lancet. , vol.350 , pp. 309-318
    • Boers, M.1    Verhoeven, A.C.2    Markusse, H.M.3    van de Laar, M.A.4    Westhovens, R.5    van Denderen, J.C.6
  • 19
    • 0027378706 scopus 로고
    • Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial
    • Clark P, Casas E, Tugwell P, Medina C, Gheno C, Tenorio G, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med. 1993;119:1067-71.
    • (1993) Ann Intern Med. , vol.119 , pp. 1067-1071
    • Clark, P.1    Casas, E.2    Tugwell, P.3    Medina, C.4    Gheno, C.5    Tenorio, G.6
  • 20
    • 0028859164 scopus 로고
    • A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study
    • A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Am J Med. 1995;98:156-68.
    • (1995) Am J Med. , vol.98 , pp. 156-168
  • 23
    • 18644373869 scopus 로고    scopus 로고
    • A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study
    • METGO Study Group.
    • Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J; METGO Study Group. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum. 2005;52:1360-70.
    • (2005) Arthritis Rheum. , vol.52 , pp. 1360-1370
    • Lehman, A.J.1    Esdaile, J.M.2    Klinkhoff, A.V.3    Grant, E.4    Fitzgerald, A.5    Canvin, J.6
  • 24
    • 2342551979 scopus 로고    scopus 로고
    • Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
    • Genovese MC, Cohen S, Moreland L,Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50:1412-9.
    • (2004) Arthritis Rheum. , vol.50 , pp. 1412-1419
    • Genovese, M.C.1    Cohen, S.2    Moreland, L.3    Lium, D.4    Robbins, S.5    Newmark, R.6
  • 25
    • 33749365296 scopus 로고    scopus 로고
    • Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic diseasemodifying antirheumatic drugs: A one-year randomized, placebo-controlled study
    • Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic diseasemodifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54: 2807-16.
    • (2006) Arthritis Rheum. , vol.54 , pp. 2807-2816
    • Weinblatt, M.1    Combe, B.2    Covucci, A.3    Aranda, R.4    Becker, J.C.5    Keystone, E.6
  • 26
    • 27744514865 scopus 로고    scopus 로고
    • Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial
    • Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381-90.
    • (2005) Arthritis Rheum. , vol.52 , pp. 3381-3390
    • Goekoop-Ruiterman, Y.P.1    De Vries-Bouwstra, J.K.2    Allaart, C.F.3    van Zeben, D.4    Kerstens, P.J.5    Hazes, JM.6
  • 27
    • 31044442965 scopus 로고    scopus 로고
    • The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
    • Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37.
    • (2006) Arthritis Rheum. , vol.54 , pp. 26-37
    • Breedveld, F.C.1    Weisman, M.H.2    Kavanaugh, A.F.3    Cohen, S.B.4    Pavelka, K.5    van Vollenhoven, R.6
  • 28
    • 67650472833 scopus 로고    scopus 로고
    • Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis
    • Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol. 2009;36:1429-41.
    • (2009) J Rheumatol. , vol.36 , pp. 1429-1441
    • Emery, P.1    Genovese, M.C.2    van Vollenhoven, R.3    Sharp, J.T.4    Patra, K.5    Sasso, E.H.6
  • 29
    • 67449124635 scopus 로고    scopus 로고
    • Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
    • Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009;68:823-7.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 823-827
    • Smolen, J.S.1    Han, C.2    van der Heijde, D.M.3    Emery, P.4    Bathon, J.M.5    Keystone, E.6
  • 30
    • 75749102955 scopus 로고    scopus 로고
    • Rapid and sustained improvements in health related quality of life, fatigue, and other patientreported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial
    • Strand V, Mease P, Burmester Nikaï, GR E, Coteur G, van Vollenhoven R, et al. Rapid and sustained improvements in health related quality of life, fatigue, and other patientreported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther. 2009;11:R170.
    • (2009) Arthritis Res Ther. , vol.11
    • Strand, V.1    Mease, P.2    Burmester, G.R.3    Nikaï, E.4    Coteur, G.5    van Vollenhoven, R.6
  • 32
    • 54949137664 scopus 로고    scopus 로고
    • Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis
    • Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 2008;59:1467-74.
    • (2008) Arthritis Rheum. , vol.59 , pp. 1467-1474
    • Bejarano, V.1    Quinn, M.2    Conaghan, P.G.3    Reece, R.4    Keenan, A.M.5    Walker, D.6
  • 33
    • 39649105036 scopus 로고    scopus 로고
    • Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA
    • Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol. 2008;35:206-15.
    • (2008) J Rheumatol. , vol.35 , pp. 206-215
    • Kimel, M.1    Cifaldi, M.2    Chen, N.3    Revicki, D.4
  • 34
    • 77950477036 scopus 로고    scopus 로고
    • Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study
    • van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman MH. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res (Hoboken). 2010;62:226-34.
    • (2010) Arthritis Care Res (Hoboken). , vol.62 , pp. 226-234
    • van Vollenhoven, R.F.1    Cifaldi, M.A.2    Ray, S.3    Chen, N.4    Weisman, M.H.5
  • 35
    • 0348109372 scopus 로고    scopus 로고
    • Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)
    • Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30:2563-71.
    • (2003) J Rheumatol. , vol.30 , pp. 2563-2571
    • Furst, D.E.1    Schiff, M.H.2    Fleischmann, R.M.3    Strand, V.4    Birbara, C.A.5    Compagnone, D.6
  • 36
    • 77953694972 scopus 로고    scopus 로고
    • Current evidence for the management of rheumatoid arthritis with biological disease modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
    • Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, etal. Current evidence for the management of rheumatoid arthritis with biological disease modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69:976-86.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 976-986
    • Nam, J.L.1    Winthrop, K.L.2    van Vollenhoven, R.F.3    Pavelka, K.4    Valesini, G.5    Hensor, E.M.6
  • 37
    • 70449514894 scopus 로고    scopus 로고
    • Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis
    • Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum. 2009;61:1592-600.
    • (2009) Arthritis Rheum. , vol.61 , pp. 1592-1600
    • Kavanaugh, A.1    Smolen, J.S.2    Emery, P.3    Purcaru, O.4    Keystone, E.5    Richard, L.6
  • 38
    • 0033524159 scopus 로고    scopus 로고
    • Infliximab (chimeric anti-tumour necrosis factor alphamonoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial
    • Maini R, St Clair EW, Breedveld F, FurstD, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alphamonoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-9.
    • (1999) ATTRACT Study Group.Lancet. , vol.354 , pp. 1932-1939
    • Maini, R.1    St Clair, E.W.2    Breedveld, F.3    Furst, D.4    Kalden, J.5    Weisman, M.6
  • 40
    • 76649140079 scopus 로고    scopus 로고
    • Abatacept for rheumatoidarthritis: a Cochrane systematic review
    • Maxwell LJ, Singh JA. Abatacept for rheumatoidarthritis: a Cochrane systematic review. J Rheumatol. 2010;37:234-45.
    • (2010) J Rheumatol. , vol.37 , pp. 234-245
    • Maxwell, L.J.1    Singh, J.A.2
  • 41
    • 65349176911 scopus 로고    scopus 로고
    • Clinical efficacy and safety of abataceptin methotrexate-naive patients with earlyrheumatoid arthritis and poor prognostic factors
    • Westhovens R, Robles M, Ximenes AC,Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abataceptin methotrexate-naive patients with earlyrheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68:1870-7.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 1870-1877
    • Westhovens, R.1    Robles, M.2    Ximenes, A.C.3    Nayiager, S.4    Wollenhaupt, J.5    Durez, P.6
  • 42
    • 80053571014 scopus 로고    scopus 로고
    • Sustained disease remission and inhibition of radiographic progression in methotrexate naïve patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes
    • Bathon J, Robles M, Ximenes AC, NayiagerS, Wollenhaupt J, Durez P, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate naïve patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis. 2011;70:1949-56.
    • (2011) Ann Rheum Dis. , vol.70 , pp. 1949-1956
    • Bathon, J.1    Robles, M.2    Ximenes, A.C.3    Nayiager, S.4    Wollenhaupt, J.5    Durez, P.6
  • 43
    • 73449097820 scopus 로고    scopus 로고
    • Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial
    • Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis. 2010;69: 222-5.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 222-225
    • Kekow, J.1    Moots, R.J.2    Emery, P.3    Durez, P.4    Koenig, A.5    Singh, A.6
  • 44
    • 68049099274 scopus 로고    scopus 로고
    • Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-näive patients with active rheumatoid arthritis: twenty-fourweek results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
    • Emery P, Fleischmann RM, MorelandLW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-näive patients with active rheumatoid arthritis: twenty-fourweek results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272-83.
    • (2009) Arthritis Rheum. , vol.60 , pp. 2272-2283
    • Emery, P.1    Fleischmann, R.M.2    Moreland, L.W.3    Hsia, E.C.4    Strusberg, I.5    Durez, P.6
  • 45
    • 77649159374 scopus 로고    scopus 로고
    • Two-year clinical and radiographic results with combination etanercept methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study
    • Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougados M, Robertson D, et al. Two-year clinical and radiographic results with combination etanercept methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum. 2010;62:674-82.
    • (2010) Arthritis Rheum. , vol.62 , pp. 674-682
    • Emery, P.1    Breedveld, F.2    van der Heijde, D.3    Ferraccioli, G.4    Dougados, M.5    Robertson, D.6
  • 46
    • 79955555067 scopus 로고    scopus 로고
    • Evaluation of an interprofessional educational intervention to improve the use of arthritis best practices in primary care
    • Lineker SC, Bell MJ, Badley EM. Evaluation of an interprofessional educational intervention to improve the use of arthritis best practices in primary care. J Rheumatol. 2011;38:931-7.
    • (2011) J Rheumatol. , vol.38 , pp. 931-937
    • Lineker, S.C.1    Bell, M.J.2    Badley, E.M.3
  • 50
    • 72249120351 scopus 로고    scopus 로고
    • Adverse events of low-to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis
    • Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ. Adverse events of low-to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68:1833-8.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 1833-1838
    • Hoes, J.N.1    Jacobs, J.W.2    Verstappen, S.M.3    Bijlsma, J.W.4    Van der Heijden, G.J.5
  • 51
    • 79958840089 scopus 로고    scopus 로고
    • Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry
    • Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, et al. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken). 2011;63:856-64.
    • (2011) Arthritis Care Res (Hoboken). , vol.63 , pp. 856-864
    • Furst, D.E.1    Pangan, A.L.2    Harrold, L.R.3    Chang, H.4    Reed, G.5    Kremer, J.M.6
  • 52
    • 79959815822 scopus 로고    scopus 로고
    • Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivides polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis)
    • Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der Heijde D. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivides polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum. 2011;63:1804-11.
    • (2011) Arthritis Rheum. , vol.63 , pp. 1804-1811
    • Lukas, C.1    Combe, B.2    Ravaud, P.3    Sibilia, J.4    Landew, R.5    van der Heijde, D.6
  • 54
    • 77954962834 scopus 로고    scopus 로고
    • A matrix risk model forthe prediction of rapid radiographic progressionin patients with rheumatoid arthritis receiving different dynamic treatments trategies: post hoc analyses from the BeStstudy
    • Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, et al. A matrix risk model forthe prediction of rapid radiographic progressionin patients with rheumatoid arthritis receiving different dynamic treatments trategies: post hoc analyses from the BeStstudy. Ann Rheum Dis. 2010;69:1333-7.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 1333-1337
    • Visser, K.1    Goekoop-Ruiterman, Y.P.2    De Vries-Bouwstra, J.K.3    Ronday, H.K.4    Seys, P.E.5    Kerstens, P.J.6
  • 55
    • 0142156483 scopus 로고    scopus 로고
    • Comparison of the efficacy of the tumour necrosis factor alphablocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis
    • Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alphablocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003;62(suppl2):ii13-6.
    • (2003) Ann Rheum Dis. , vol.62 , Issue.SUPPl 2 , pp. 213-216
    • Hochberg, M.C.1    Tracy, J.K.2    Hawkins-Holt, M.3    Flores, R.H.4
  • 56
    • 74849094402 scopus 로고    scopus 로고
    • Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in thenation wide Danish DANBIO registry
    • Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in thenation wide Danish DANBIO registry. Arthritis Rheum. 2010;62:22-32.
    • (2010) Arthritis Rheum. , vol.62 , pp. 22-32
    • Hetland, M.L.1    Christensen, I.J.2    Tarp, U.3    Dreyer, L.4    Hansen, A.5    Hansen, I.T.6
  • 57
    • 67549115310 scopus 로고    scopus 로고
    • Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis
    • van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ, et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis. 2009;68:1153-8.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 1153-1158
    • van der Kooij, S.M.1    le Cessie, S.2    Goekoop-Ruiterman, Y.P.3    De Vries-Bouwstra, J.K.4    van Zeben, D.5    Kerstens, P.J.6
  • 58
    • 68049124945 scopus 로고    scopus 로고
    • Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquineto methotrexate in patients with early rheumatoid arthritis (Swefottrial): 1-year results of a randomised trial
    • van Vollenhoven RF, Ernestam S, GeborekP, Petersson IF, Cöster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquineto methotrexate in patients with early rheumatoid arthritis (Swefottrial): 1-year results of a randomised trial. Lancet. 2009;374:459-66.
    • (2009) Lancet. , vol.374 , pp. 459-466
    • van Vollenhoven, R.F.1    Ernestam, S.2    Geborek, P.3    Petersson, I.F.4    Cöster, L.5    Waltbrand, E.6
  • 59
    • 0036274944 scopus 로고    scopus 로고
    • Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes
    • Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443-50.
    • (2002) Arthritis Rheum. , vol.46 , pp. 1443-1450
    • Genovese, M.C.1    Bathon, J.M.2    Martin, R.W.3    Fleischmann, R.M.4    Tesser, J.R.5    Schiff, M.H.6
  • 60
    • 77953701867 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
    • Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis. 2010;69:1129-35.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 1129-1135
    • Keystone, E.1    Genovese, MC.2    Klareskog, L.3    Hsia, E.C.4    Hall, S.5    Miranda, P.C.6
  • 61
    • 34247218183 scopus 로고    scopus 로고
    • Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists
    • Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56:1125-33.42
    • (2007) Arthritis Rheum. , vol.56 , pp. 1125-3342
    • Curtis, J.R.1    Patkar, N.2    Xie, A.3    Martin, C.4    Allison, J.J.5    Saag, M.6
  • 62
    • 34848839939 scopus 로고    scopus 로고
    • Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies
    • British Society for Rheumatology Biologics Register Control Centre Consortium et al.
    • Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL; British Society for Rheumatology Biologics Register Control Centre Consortium, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56:2896-904.
    • (2007) Arthritis Rheum. , vol.56 , pp. 2896-2904
    • Dixon, W.G.1    Symmons, D.P.2    Lunt, M.3    Watson, K.D.4    Hyrich, K.L.5
  • 63
    • 70449725246 scopus 로고    scopus 로고
    • Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
    • Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1739-45.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 1739-1745
    • Radstake, T.R.1    Svenson, M.2    Eijsbouts, A.M.3    Van Den Hoogen, F.H.4    Enevold, C.5    Van Riel, P.L.6
  • 64
    • 77951548027 scopus 로고    scopus 로고
    • Anti-infliximab and antiadalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naïve patients: a cohort study
    • Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Anti-infliximab and antiadalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naïve patients: a cohort study. Ann Rheum Dis. 2010;69:817-21.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 817-821
    • Bartelds, G.M.1    Wijbrandts, C.A.2    Nurmohamed, M.T.3    Stapel, S.4    Lems, W.F.5    Aarden, L.6
  • 65
    • 0036169930 scopus 로고    scopus 로고
    • Guidelines for the management of rheumatoid arthritis
    • American College of Rheumatology Subcommittee on rheumatoid arthritis guidelines.
    • American College of Rheumatology Subcommittee on rheumatoid arthritis guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 2002;46:328-46.
    • (2002) Arthritis Rheum. , vol.46 , pp. 328-346
  • 66
    • 77953696525 scopus 로고    scopus 로고
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    • Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 964-975
    • Smolen, J.S.1    Landewé, R.2    Breedveld, F.C.3    Dougados, M.4    Emery, P.5    Gaujoux-Viala, C.6
  • 67
    • 77957859697 scopus 로고    scopus 로고
    • Use of glucocorticoids in rheumatoid arthritis -pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion
    • Dernis E, Ruyssen-Witrand A, Mouterde G, Maillefert JF, Tebib J, Cantagrel A, et al. Use of glucocorticoids in rheumatoid arthritis -pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion. Jt, Bone, Spine. 2010;77:451-7.
    • (2010) Jt, Bone, Spine. , vol.77 , pp. 451-457
    • Dernis, E.1    Ruyssen-Witrand, A.2    Mouterde, G.3    Maillefert, J.F.4    Tebib, J.5    Cantagrel, A.6
  • 68
    • 78650528837 scopus 로고    scopus 로고
    • How does methotrexate suppress inflammation
    • Cronstein B. How does methotrexate suppress inflammation? Clin Exp Rheumatol. 2010;28(5 Suppl 61):S21-3.
    • (2010) Clin Exp Rheumatol , vol.28 , Issue.5-61 SUPPL
    • Cronstein, B.1
  • 69
    • 78650581157 scopus 로고    scopus 로고
    • Methotrexate -the anchor drug -an introduction
    • Pincus T, Cronstein B, Braun J. Methotrexate -the anchor drug -an introduction. Clin Exp Rheumatol. 2010;28(Suppl 61):S1-2.
    • (2010) Clin Exp Rheumatol. , vol.28-61 , Issue.SUPPL
    • Pincus, T.1    Cronstein, B.2    Braun, J.3
  • 70
    • 70449688246 scopus 로고    scopus 로고
    • National recommendations based on scientific evidence and opinions of experts on the use of methotrexate in rheumatic disorders, especially in rheumatoid arthritis: results of the 3E Initiative from Brazil
    • Pereira IA, Cruz BA, Xavier RM, Pinheiro GR, Titton D, Giorgi R, et al. National recommendations based on scientific evidence and opinions of experts on the use of methotrexate in rheumatic disorders, especially in rheumatoid arthritis: results of the 3E Initiative from Brazil. Rev Bras Reumatol. 2009;49:346-61.
    • (2009) Rev Bras Reumatol. , vol.49 , pp. 346-361
    • Pereira, I.A.1    Cruz, B.A.2    Xavier, R.M.3    Pinheiro, G.R.4    Titton, D.5    Giorgi, R.6
  • 71
    • 0036310615 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of leflunomide
    • Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet. 2002;41:421-30.
    • (2002) Clin Pharmacokinet. , vol.41 , pp. 421-430
    • Rozman, B.1
  • 72
    • 79551548116 scopus 로고    scopus 로고
    • Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy
    • American Academy of Ophthalmology.
    • Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415-22.
    • (2011) Ophthalmology. , vol.118 , pp. 415-422
    • Marmor, M.F.1    Kellner, U.2    Lai, T.Y.3    Lyons, J.S.4    Mieler, W.F.5
  • 73
    • 80055068987 scopus 로고    scopus 로고
    • Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I
    • Caporali R Conti F, Alivernini S, Atzeni F, Seriolo B, Cutolo M, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol. 2011;29: S7-14.
    • (2011) Efficacy. Clin Exp Rheumatol. , vol.29
    • Caporali, R.1    Conti, F.2    Alivernini, S.3    Atzeni, F.4    Seriolo, B.5    Cutolo, M.6
  • 74
    • 80055082433 scopus 로고    scopus 로고
    • Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II
    • Favalli EG, Caporali R, Sinigaglia L, Pipitone N, Miniati I, Montecucco C, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. Clin Exp Rheumatol. 2011;29:S15-27.
    • (2011) Safety.Clin Exp Rheumatol. , vol.29
    • Favalli, E.G.1    Caporali, R.2    Sinigaglia, L.3    Pipitone, N.4    Miniati, I.5    Montecucco, C.6
  • 77
    • 67549096874 scopus 로고    scopus 로고
    • Multinational evidencebased recommendations for the use of methotrexate in rheumatic disorders with afocus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative
    • Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidencebased recommendations for the use of methotrexate in rheumatic disorders with afocus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68(7):1086-93
    • (2009) Ann Rheum Dis. , vol.68 , Issue.7 , pp. 1086-1093
    • Visser, K.1    Katchamart, W.2    Loza, E.3    Martinez-Lopez, J.A.4    Salliot, C.5    Trudeau, J.6
  • 78
    • 84883249452 scopus 로고    scopus 로고
    • Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute.
    • 2011 Jul 15. [Epub ahead of print]
    • Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute. Mod Rheumatol. 2011 Jul 15. [Epub ahead of print].
    • Mod Rheumatol
  • 81
    • 33746961890 scopus 로고    scopus 로고
    • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    • Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54: 2793-806.
    • (2006) Arthritis Rheum. , vol.54 , pp. 2793-2806
    • Cohen, S.B.1    Emery, P.2    Greenwald, M.W.3    Dougados, M.4    Furie, R.A.5    Genovese, M.C.6
  • 82
    • 77955896561 scopus 로고    scopus 로고
    • Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebocontrolled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
    • Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebocontrolled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629-35.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 1629-1635
    • Emery, P.1    Deodhar, A.2    Rigby, W.F.3    Isaacs, J.D.4    Combe, B.5    Racewicz, A.J.6
  • 83
    • 58849088519 scopus 로고    scopus 로고
    • Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies
    • Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2009;68:216-21.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 216-221
    • Keystone, E.1    Emery, P.2    Peterfy, C.G.3    Tak, P.P.4    Cohen, S.5    Genovese, M.C.6
  • 84
    • 80051473134 scopus 로고    scopus 로고
    • Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
    • Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575-80.
    • (2011) Ann Rheum Dis. , vol.70 , pp. 1575-1580
    • Chatzidionysiou, K.1    Lie, E.2    Nasonov, E.3    Lukina, G.4    Hetland, M.L.5    Tarp, U.6
  • 85
    • 56349118815 scopus 로고    scopus 로고
    • Abatacept and serious respiratory infections in patients with previous lung disease
    • Miller KL, Sawitzke AD, Doane J. Abatacept and serious respiratory infections in patients with previous lung disease. Clin Rheumatol. 2008;27:1569-71.
    • (2008) Clin Rheumatol. , vol.27 , pp. 1569-1571
    • Miller, K.L.1    Sawitzke, A.D.2    Doane, J.3
  • 86
    • 34047142747 scopus 로고    scopus 로고
    • Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs
    • Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford). 2007;46:626-30.
    • (2007) Rheumatology (Oxford). , vol.46 , pp. 626-630
    • Popa, C.1    Leandro, M.J.2    Cambridge, G.3    Edwards, J.C.4
  • 87
    • 79952013541 scopus 로고    scopus 로고
    • Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta analysis of randomized controlled trials
    • Campbell L, Chen C, Bhagat SS, ParkerRA, Östör AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50:552-62.
    • (2011) Rheumatology (Oxford). , vol.50 , pp. 552-562
    • Campbell, L.1    Chen, C.2    Bhagat, S.S.3    Parker, R.A.4    Östör, A.J.5
  • 88
    • 78650907772 scopus 로고    scopus 로고
    • Tocilizumab for rheumatoid arthritis: a Cochrane systematic review
    • Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2011;38:10-20.
    • (2011) J Rheumatol. , vol.38 , pp. 10-20
    • Singh, J.A.1    Beg, S.2    Lopez-Olivo, M.A.3
  • 89
    • 80755182205 scopus 로고    scopus 로고
    • Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review
    • Gout T, Ostör AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol. 2011;30:1471-4.
    • (2011) Clin Rheumatol. , vol.30 , pp. 1471-1474
    • Gout, T.1    Ostör, A.J.2    Nisar, M.K.3
  • 94
    • 77953718691 scopus 로고    scopus 로고
    • Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
    • Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester GR, Combe B, et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:987-94.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 987-994
    • Knevel, R.1    Schoels, M.2    Huizinga, T.W.3    Aletaha, D.4    Burmester, G.R.5    Combe, B.6
  • 95
    • 77952467678 scopus 로고    scopus 로고
    • Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis
    • Katchamart W, Trudeau J, PhumethumV, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev. 2010;14 (4):CD008495.
    • (2010) Cochrane Database Syst Rev. , vol.14 , Issue.4
    • Katchamart, W.1    Trudeau, J.2    Phumethum, V.3    Bombardier, C.4
  • 96
    • 73449118587 scopus 로고    scopus 로고
    • Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
    • Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88-96.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 88-96
    • Jones, G.1    Sebba, A.2    Gu, J.3    Lowenstein, M.B.4    Calvo, A.5    Gomez-Reino, J.J.6
  • 98
    • 0031786151 scopus 로고    scopus 로고
    • A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis
    • Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R. A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol. 1998; 37:1060-8.
    • (1998) Br J Rheumatol. , vol.37 , pp. 1060-1068
    • Menninger, H.1    Herborn, G.2    Sander, O.3    Blechschmidt, J.4    Rau, R.5
  • 99
    • 0033496274 scopus 로고    scopus 로고
    • Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: atwenty-four week, single blind, randomized study
    • Luis M, Pacheco-Tena C, Cazarín-Barrientos J, Lino-Pérez L, Goycochea MV, Vazquez-Mellado J, et al. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: atwenty-four week, single blind, randomized study. Arthritis Rheum. 1999;42:2160-5.
    • (1999) Arthritis Rheum. , vol.42 , pp. 2160-2165
    • Luis, M.1    Pacheco-Tena, C.2    Cazarín-Barrientos, J.3    Lino-Pérez, L.4    Goycochea, M.V.5    Vazquez-Mellado, J.6
  • 101
    • 19944431840 scopus 로고    scopus 로고
    • Very early treatment with infliximab in addition to methotrexate in early, poor prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, doubleblind, placebo-controlled trial
    • Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 2005;52:27-35.
    • (2005) Arthritis Rheum. , vol.52 , pp. 27-35
    • Quinn, M.A.1    Conaghan, P.G.2    O'Connor, P.J.3    Karim, Z.4    Greenstein, A.5    Brown, A.6
  • 102
    • 67449124635 scopus 로고    scopus 로고
    • Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
    • Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009;68:823-7.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 823-827
    • Smolen, J.S.1    Han, C.2    van der Heijde, D.M.3    Emery, P.4    Bathon, J.M.5    Keystone, E.6
  • 103
    • 27444447706 scopus 로고    scopus 로고
    • Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results
    • van der Heijde D, Klareskog L, Boers M, Landewé R, Codreanu C, Bolosiu HD, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis. 2005;64:1582-7.
    • (2005) Ann Rheum Dis. , vol.64 , pp. 1582-1587
    • van der Heijde, D.1    Klareskog, L.2    Boers, M.3    Landewé, R.4    Codreanu, C.5    Bolosiu, H.D.6
  • 104
    • 37149038223 scopus 로고    scopus 로고
    • Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis
    • van der Heijde D, Klareskog L, Landewé R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:3928-39.
    • (2007) Arthritis Rheum. , vol.56 , pp. 3928-3939
    • van der Heijde, D.1    Klareskog, L.2    Landewé, R.3    Bruyn, G.A.4    Cantagrel, A.5    Durez, P.6
  • 105
    • 48149100741 scopus 로고    scopus 로고
    • Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
    • Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375-82.
    • (2008) Lancet. , vol.372 , pp. 375-382
    • Emery, P.1    Breedveld, F.C.2    Hall, S.3    Durez, P.4    Chang, D.J.5    Robertson, D.6
  • 106
    • 33744479185 scopus 로고    scopus 로고
    • Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
    • Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 2006;65:753-9.
    • (2006) Ann Rheum Dis. , vol.65 , pp. 753-759
    • Weinblatt, M.E.1    Keystone, E.C.2    Furst, D.E.3    Kavanaugh, A.F.4    Chartash, E.K.5    Segurado, O.G.6
  • 107
    • 66049094003 scopus 로고    scopus 로고
    • Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment
    • Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum. 2009;60:1242-9.
    • (2009) Arthritis Rheum. , vol.60 , pp. 1242-1249
    • Aletaha, D.1    Funovits, J.2    Breedveld, F.C.3    Sharp, J.4    Segurado, O.5    Smolen, J.S.6
  • 108
    • 79952362560 scopus 로고    scopus 로고
    • Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort
    • Soubrier M, Lukas C, Sibilia J, Fautrel B, Roux F, Gossec L, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis. 2011;70:611-5.
    • (2011) Ann Rheum Dis. , vol.70 , pp. 611-615
    • Soubrier, M.1    Lukas, C.2    Sibilia, J.3    Fautrel, B.4    Roux, F.5    Gossec, L.6
  • 111
    • 19944433899 scopus 로고    scopus 로고
    • Early suppression of disease activity isessential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RA Cotrial
    • Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, et al. Early suppression of disease activity isessential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RA Cotrial. Arthritis Rheum. 2005;52:36-41.
    • (2005) Arthritis Rheum. , vol.52 , pp. 36-41
    • Puolakka, K.1    Kautiainen, H.2    Möttönen, T.3    Hannonen, P.4    Korpela, M.5    Hakala, M.6
  • 112
    • 66049150438 scopus 로고    scopus 로고
    • The good initial response to therapy with a combination of traditional diseasemodifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial
    • Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, et al. The good initial response to therapy with a combination of traditional diseasemodifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum. 2009;60:1222-31.
    • (2009) Arthritis Rheum. , vol.60 , pp. 1222-1231
    • Rantalaiho, V.1    Korpela, M.2    Hannonen, P.3    Kautiainen, H.4    Järvenpää, S.5    Leirisalo-Repo, M.6
  • 113
    • 79955856735 scopus 로고    scopus 로고
    • The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study
    • Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011;70:1039-46.
    • (2011) Ann Rheum Dis. , vol.70 , pp. 1039-1046
    • Klarenbeek, N.B.1    Güler-Yüksel, M.2    van der Kooij, S.M.3    Han, K.H.4    Ronday, H.K.5    Kerstens, P.J.6
  • 115
    • 77951246294 scopus 로고    scopus 로고
    • Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis
    • Todoerti M, Sciré CA, Boffini N, BugattiS, Montecucco C, Caporali R. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann N Y Acad Sci. 2010;1193:139-45.
    • (2010) Ann N Y Acad Sci. , vol.1193 , pp. 139-145
    • Todoerti, M.1    Sciré, C.A.2    Boffini, N.3    Bugatti, S.4    Montecucco, C.5    Caporali, R.6
  • 116
    • 78751703180 scopus 로고    scopus 로고
    • Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study
    • Klarenbeek NB, van der Kooij SM, Güler-Yüksel M, van Groenendael JH, Han KH, Kerstens PJ, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis. 2011;70:315-9.
    • (2011) Ann Rheum Dis. , vol.70 , pp. 315-319
    • Klarenbeek, N.B.1    van der Kooij, S.M.2    Güler-Yüksel, M.3    van Groenendael, J.H.4    Han, K.H.5    Kerstens, P.J.6
  • 117
    • 33846976105 scopus 로고    scopus 로고
    • Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis
    • Mäkinen H, Kautiainen H, Hannonen P, Möttönen T, Leirisalo-Repo M, Laasonen L, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol. 2007;34:316-21.
    • (2007) J Rheumatol. , vol.34 , pp. 316-321
    • Mäkinen, H.1    Kautiainen, H.2    Hannonen, P.3    Möttönen, T.4    Leirisalo-Repo, M.5    Laasonen, L.6
  • 118
    • 84863979452 scopus 로고    scopus 로고
    • The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study
    • physicians of SCQMRA.
    • Kyburz D, Gabay C, Michel BA, FinckhA; physicians of SCQMRA. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology (Oxford). 2011;50:1106-10.
    • (2011) Rheumatology (Oxford). , vol.50 , pp. 1106-1110
    • Kyburz, D.1    Gabay, C.2    Michel, B.A.3    Finckh, A.4
  • 119
    • 33845506003 scopus 로고    scopus 로고
    • Longterm impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis
    • Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Longterm impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum. 2006; 55:864-72.
    • (2006) Arthritis Rheum. , vol.55 , pp. 864-872
    • Finckh, A.1    Liang, M.H.2    van Herckenrode, C.M.3    De Pablo, P.4
  • 120
    • 3242886819 scopus 로고    scopus 로고
    • Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis
    • Nell VP, Machold KP, Eberl G, StammTA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:906-14.
    • (2004) Rheumatology (Oxford). , vol.43 , pp. 906-914
    • Nell, V.P.1    Machold, K.P.2    Eberl, G.3    Stamm, T.A.4    Uffmann, M.5    Smolen, J.S.6
  • 121
    • 77949664602 scopus 로고    scopus 로고
    • Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis
    • Weng HH, Ranganath VK, Khanna D, Oh M, Furst DE, Park GS, et al. Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis. J Rheumatol. 2010; 37: 550-7.
    • (2010) J Rheumatol. , vol.37 , pp. 550-557
    • Weng, H.H.1    Ranganath, V.K.2    Khanna, D.3    Oh, M.4    Furst, D.E.5    Park, G.S.6
  • 122
    • 78650656379 scopus 로고    scopus 로고
    • Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis
    • Haugeberg G, Morton S, Emery P, Conaghan PG. Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis. Ann Rheum Dis. 2011;70:184-7.
    • (2011) Ann Rheum Dis. , vol.70 , pp. 184-187
    • Haugeberg, G.1    Morton, S.2    Emery, P.3    Conaghan, P.G.4
  • 123
    • 77949438480 scopus 로고    scopus 로고
    • The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis
    • Machold KP, Landewé R, Smolen JS, Stamm TA, van der Heijde DM, Verpoort KN, et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis. 2010;69:495-502.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 495-502
    • Machold, K.P.1    Landewé, R.2    Smolen, J.S.3    Stamm, T.A.4    van der Heijde, D.M.5    Verpoort, K.N.6
  • 124
    • 70449730889 scopus 로고    scopus 로고
    • Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial
    • Pincus T, Swearingen CJ, Luta G, Sokka T. Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis. 2009;68:1715-20.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 1715-1720
    • Pincus, T.1    Swearingen, C.J.2    Luta, G.3    Sokka, T.4
  • 125
    • 42449088470 scopus 로고    scopus 로고
    • Factorial randomized controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis
    • Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, et al. Factorial randomized controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis. 2008;67:656-63.
    • (2008) Ann Rheum Dis. , vol.67 , pp. 656-663
    • Choy, E.H.1    Smith, C.M.2    Farewell, V.3    Walker, D.4    Hassell, A.5    Chau, L.6
  • 126
    • 42949168291 scopus 로고    scopus 로고
    • Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
    • S126-35PMID:18240203
    • Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2008;58(2Suppl):S126-35PMID:18240203.
    • (2008) Arthritis Rheum. , vol.58 , Issue.2 SUPPL
    • Goekoop-Ruiterman, Y.P.1    De Vries-Bouwstra, J.K.2    Allaart, C.F.3    van Zeben, D.4    Kerstens, P.J.5    Hazes, J.M.6
  • 127
    • 34548187949 scopus 로고    scopus 로고
    • Patient preferences for treatment: report from a randomized comparison of treatment strategies in early rheumatoid arthritis (BeSt trial)
    • Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Kerstens PJ, Grillet BA, de Jager MH, et al. Patient preferences for treatment: report from a randomized comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis. 2007;66:1227-32.
    • (2007) Ann Rheum Dis. , vol.66 , pp. 1227-1232
    • Goekoop-Ruiterman, Y.P.1    De Vries-Bouwstra, J.K.2    Allaart, C.F.3    Kerstens, P.J.4    Grillet, B.A.5    De Jager, M.H.6
  • 128
    • 27744466694 scopus 로고    scopus 로고
    • Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two year randomized trial
    • Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two year randomized trial. Arthritis Rheum. 2005;52:3360-70.
    • (2005) Arthritis Rheum. , vol.52 , pp. 3360-3370
    • Svensson, B.1    Boonen, A.2    Albertsson, K.3    van der Heijde, D.4    Keller, C.5    Hafström, I.6
  • 129
    • 2442716571 scopus 로고    scopus 로고
    • A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis
    • Kirwan JR, Hällgren R, Mielants H, Wollheim F, Bjorck E, Persson T, et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis. 2004; 63: 688-95.
    • (2004) Ann Rheum Dis. , vol.63 , pp. 688-695
    • Kirwan, J.R.1    Hällgren, R.2    Mielants, H.3    Wollheim, F.4    Bjorck, E.5    Persson, T.6
  • 130
    • 0036140321 scopus 로고    scopus 로고
    • Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial
    • van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136:1-12.
    • (2002) Ann Intern Med. , vol.136 , pp. 1-12
    • van Everdingen, A.A.1    Jacobs, J.W.2    Siewertsz Van Reesema, D.R.3    Bijlsma, J.W.4
  • 131
    • 0242500367 scopus 로고    scopus 로고
    • Low dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures
    • van Everdingen AA, Siewertsz van ReesemaDR, Jacobs JW, Bijlsma JW. Low dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clin Exp Rheumatol. 2003; 21:155-60.
    • (2003) Clin Exp Rheumatol. , vol.21 , pp. 155-160
    • van Everdingen, A.A.1    Siewertsz van Reesema, D.R.2    Jacobs, J.W.3    Bijlsma, J.W.4
  • 133
    • 0038681584 scopus 로고    scopus 로고
    • Five-year followup of rheumatoid arthritis patients after early treatment with disease modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year
    • Verstappen SM, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, Borg EJ, et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum. 2003;48:1797-807.
    • (2003) Arthritis Rheum. , vol.48 , pp. 1797-1807
    • Verstappen, S.M.1    Jacobs, J.W.2    Bijlsma, J.W.3    Heurkens, A.H.4    van Booma-Frankfort, C.5    Borg, E.J.6
  • 134
    • 0036021129 scopus 로고    scopus 로고
    • A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis
    • Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002;29:1623-30.
    • (2002) J Rheumatol. , vol.29 , pp. 1623-1630
    • Matsumoto, A.K.1    Melian, A.2    Mandel, D.R.3    McIlwain, H.H.4    Borenstein, D.5    Zhao, P.L.6
  • 135
    • 34248674068 scopus 로고    scopus 로고
    • A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis
    • Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract. 2002;3:10.
    • (2002) BMC Fam Pract. , vol.3 , pp. 10
    • Collantes, E.1    Curtis, S.P.2    Lee, K.W.3    Casas, N.4    McCarthy, T.5    Melian, A.6
  • 136
    • 0036558915 scopus 로고    scopus 로고
    • Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium
    • Choy EH, Scott DL, Kingsley GH, Williams P, Wojtulewski J, Papasavvas G, et al. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol. 2002;20:351-8.
    • (2002) Clin Exp Rheumatol. , vol.20 , pp. 351-358
    • Choy, E.H.1    Scott, D.L.2    Kingsley, G.H.3    Williams, P.4    Wojtulewski, J.5    Papasavvas, G.6
  • 139
    • 0033601089 scopus 로고    scopus 로고
    • Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial
    • Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921-8.
    • (1999) JAMA. , vol.282 , pp. 1921-1928
    • Simon, L.S.1    Weaver, A.L.2    Graham, D.Y.3    Kivitz, A.J.4    Lipsky, P.E.5    Hubbard, R.C.6
  • 140
    • 0033582115 scopus 로고    scopus 로고
    • Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized doubleblind comparison
    • Emery P, Zeidler H, Kvien TK, GuslandiM, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized doubleblind comparison. Lancet. 1999;354:2106-11.
    • (1999) Lancet. , vol.354 , pp. 2106-2111
    • Emery, P.1    Zeidler, H.2    Kvien, T.K.3    Guslandi, M.4    Naudin, R.5    Stead, H.6
  • 142
    • 34447503875 scopus 로고    scopus 로고
    • Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone
    • Fiehn C, Jacki S, Heilig B, Lampe M, Wiesmüller G, Richter C, et al. Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone. Rheumatol Int. 2007;27:975-9.
    • (2007) Rheumatol Int. , vol.27 , pp. 975-979
    • Fiehn, C.1    Jacki, S.2    Heilig, B.3    Lampe, M.4    Wiesmüller, G.5    Richter, C.6
  • 143
    • 0038657686 scopus 로고    scopus 로고
    • Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta analysis
    • Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta analysis. J Rheumatol. 2003;30:1182-90.
    • (2003) J Rheumatol. , vol.30 , pp. 1182-1190
    • Osiri, M.1    Shea, B.2    Robinson, V.3    Suarez-Almazor, M.4    Strand, V.5    Tugwell, P.6
  • 144
    • 0036169558 scopus 로고    scopus 로고
    • Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging
    • Reece RJ, Kraan MC, Radjenovic A, Veale DJ, O'Connor PJ, Ridgway JP, et al. Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum. 2002;46:366-72.
    • (2002) Arthritis Rheum. , vol.46 , pp. 366-372
    • Reece, R.J.1    Kraan, M.C.2    Radjenovic, A.3    Veale, D.J.4    O'Connor, P.J.5    Ridgway, J.P.6
  • 146
    • 6744262231 scopus 로고    scopus 로고
    • A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis
    • Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2000;39: 655-65.
    • (2000) Rheumatology (Oxford). , vol.39 , pp. 655-665
    • Emery, P.1    Breedveld, F.C.2    Lemmel, E.M.3    Kaltwasser, J.P.4    Dawes, P.T.5    Gömör, B.6
  • 147
    • 0034123087 scopus 로고    scopus 로고
    • Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis
    • Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 2000;43:495-505.
    • (2000) Leflunomide Rheumatoid Arthritis Investigators Group.Arthritis Rheum. , vol.43 , pp. 495-505
    • Sharp, J.T.1    Strand, V.2    Leung, H.3    Hurley, F.4    Loew-Friedrich, I.5
  • 149
    • 0033495154 scopus 로고    scopus 로고
    • Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis
    • Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 1999;42:1870-8.
    • (1999) Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. , vol.42 , pp. 1870-1878
    • Strand, V.1    Tugwell, P.2    Bombardier, C.3    Maetzel, A.4    Crawford, B.5    Dorrier, C.6
  • 150
    • 0026040238 scopus 로고
    • A double-blind comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: an interim report on 102 patients after 12 months
    • Rau R, Herborn G, Karger T, Menninger H, Elhardt D, Schmitt J. A double-blind comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: an interim report on 102 patients after 12 months. Semin Arthritis Rheum. 1991;21(2 Suppl 1):13-20.
    • (1991) Semin Arthritis Rheum. , vol.21 , Issue.2 SUPPL 1 , pp. 13-20
    • Rau, R.1    Herborn, G.2    Karger, T.3    Menninger, H.4    Elhardt, D.5    Schmitt, J.6
  • 151
    • 0025892324 scopus 로고
    • A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis
    • Rau R, Herborn G, Karger T, Menninger H, Elhardt D, Schmitt J. A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. J Rheumatol. 1991;18:328-33.
    • (1991) J Rheumatol. , vol.18 , pp. 328-333
    • Rau, R.1    Herborn, G.2    Karger, T.3    Menninger, H.4    Elhardt, D.5    Schmitt, J.6
  • 152
    • 0023944685 scopus 로고
    • A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatment of rheumatoid arthritis
    • Suarez-Almazor ME, Fitzgerald A, Grace M, Russell AS. A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatment of rheumatoid arthritis. J Rheumatol. 1988;15:753-6.
    • (1988) J Rheumatol. , vol.15 , pp. 753-756
    • Suarez-Almazor, M.E.1    Fitzgerald, A.2    Grace, M.3    Russell, A.S.4
  • 153
    • 0030872831 scopus 로고    scopus 로고
    • Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a doubleblind parallel study of 174 patients
    • Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a doubleblind parallel study of 174 patients. Br J Rheumatol. 1997;36: 345-52.
    • (1997) Br J Rheumatol. , vol.36 , pp. 345-352
    • Rau, R.1    Herborn, G.2    Menninger, H.3    Blechschmidt, J.4
  • 154
    • 0031787944 scopus 로고    scopus 로고
    • Progression in early erosive rheumatoid arthritis: 12 month results froma randomized controlled trial comparing methotrexate and gold sodium thiomalate
    • Rau R, Herborn G, Menninger H, Sangha O. Progression in early erosive rheumatoid arthritis: 12 month results froma randomized controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol. 1998;37:1220-6.
    • (1998) Br J Rheumatol. , vol.37 , pp. 1220-1226
    • Rau, R.1    Herborn, G.2    Menninger, H.3    Sangha, O.4
  • 155
    • 36048996294 scopus 로고    scopus 로고
    • Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial -an Indian experience
    • Das SK, Pareek A, Mathur DS, WanchuA, Srivastava R, Agarwal GG, et al. Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial -an Indian experience. Curr Med Res Opin. 2007; 23: 2227-34.
    • (2007) Curr Med Res Opin. , vol.23 , pp. 2227-2234
    • Das, S.K.1    Pareek, A.2    Mathur, D.S.3    Wanchu, A.4    Srivastava, R.5    Agarwal, G.G.6
  • 156
    • 0034101655 scopus 로고    scopus 로고
    • Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study
    • Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M'Seffar A, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol. 2000; 27: 623-9.
    • (2000) J Rheumatol. , vol.27 , pp. 623-629
    • Tsakonas, E.1    Fitzgerald, A.A.2    Fitzcharles, M.A.3    Cividino, A.4    Thorne, J.C.5    M'Seffar, A.6
  • 157
    • 0033044368 scopus 로고    scopus 로고
    • Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six week trial with eighteen-week extension
    • Furst DE, Lindsley H, Baethge B, BotsteinGR, Caldwell J, Dietz F, et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six week trial with eighteen-week extension. Arthritis Rheum. 1999; 42: 357-65.
    • (1999) Arthritis Rheum. , vol.42 , pp. 357-365
    • Furst, D.E.1    Lindsley, H.2    Baethge, B.3    Botstein, G.R.4    Caldwell, J.5    Dietz, F.6
  • 158
    • 0030862557 scopus 로고    scopus 로고
    • Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine
    • Clegg DO, Dietz F, Duffy J, Willkens RF, Hurd E, Germain BF, et al. Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol. 1997;24:1896-902.
    • (1997) J Rheumatol. , vol.24 , pp. 1896-1902
    • Clegg, D.O.1    Dietz, F.2    Duffy, J.3    Willkens, R.F.4    Hurd, E.5    Germain, B.F.6
  • 159
    • 0027490124 scopus 로고
    • Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis
    • Trnavský K, Gatterová J, Lindusková M, Pelisková Z. Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis. Z Rheumatol. 1993;52:292-6.
    • (1993) Z Rheumatol. , vol.52 , pp. 292-296
    • Trnavský, K.1    Gatterová, J.2    Lindusková, M.3    Pelisková, Z.4
  • 160
    • 0027241158 scopus 로고
    • Combination therapy in rheumatoid arthritis -no benefit of addition of hydroxychloroquineto patients with a suboptimal response to intramuscular gold therapy
    • Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis -no benefit of addition of hydroxychloroquineto patients with a suboptimal response to intramuscular gold therapy. J Rheumatol. 1993;20:645-9.
    • (1993) J Rheumatol. , vol.20 , pp. 645-649
    • Porter, D.R.1    Capell, H.A.2    Hunter, J.3
  • 161
    • 2342658406 scopus 로고    scopus 로고
    • Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial
    • Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-11.
    • (2004) Arthritis Rheum. , vol.50 , pp. 1400-1411
    • Keystone, E.C.1    Kavanaugh, A.F.2    Sharp, J.T.3    Tannenbaum, H.4    Hua, Y.5    Teoh, L.S.6
  • 162
    • 79955556511 scopus 로고    scopus 로고
    • Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis
    • Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. J Rheumatol. 2011;38:855-62.
    • (2011) J Rheumatol. , vol.38 , pp. 855-862
    • Keystone, E.C.1    Kavanaugh, A.2    Weinblatt, M.E.3    Patra, K.4    Pangan, A.L.5
  • 163
    • 0037231533 scopus 로고    scopus 로고
    • Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial
    • Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45.
    • (2003) Arthritis Rheum. , vol.48 , pp. 35-45
    • Weinblatt, M.E.1    Keystone, E.C.2    Furst, D.E.3    Moreland, L.W.4    Weisman, M.H.5    Birbara, C.A.6
  • 164
    • 55849112632 scopus 로고    scopus 로고
    • Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, doubleblind, placebo-controlled, parallel-group study
    • Keystone E, Heijde D, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, doubleblind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58:3319-29.
    • (2008) Arthritis Rheum. , vol.58 , pp. 3319-3329
    • Keystone, E.1    Heijde, D.2    Mason, D.3    Landewé, R.4    Vollenhoven, R.V.5    Combe, B.6
  • 165
    • 84860390175 scopus 로고    scopus 로고
    • RAPID3 (RoutineAssessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS-28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol
    • Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K. RAPID3 (RoutineAssessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS-28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken). 2011;63:1142-9.
    • (2011) Arthritis Care Res (Hoboken). , vol.63 , pp. 1142-1149
    • Pincus, T.1    Furer, V.2    Keystone, E.3    Yazici, Y.4    Bergman, M.J.5    Luijtens, K.6
  • 166
    • 79952215359 scopus 로고    scopus 로고
    • American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial
    • van Vollenhoven RF, Felson D, Strand V, Weinblatt ME, Luijtens K, Keystone EC. American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial. Arthritis Care Res (Hoboken). 2011;63:128-34.
    • (2011) Arthritis Care Res (Hoboken). , vol.63 , pp. 128-134
    • van Vollenhoven, R.F.1    Felson, D.2    Strand, V.3    Weinblatt, M.E.4    Luijtens, K.5    Keystone, E.C.6
  • 167
    • 33750372498 scopus 로고    scopus 로고
    • Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison
    • Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis. 2006;65:1357-62.
    • (2006) Ann Rheum Dis. , vol.65 , pp. 1357-1362
    • Combe, B.1    Codreanu, C.2    Fiocco, U.3    Gaubitz, M.4    Geusens, P.P.5    Kvien, T.K.6
  • 168
    • 67549130666 scopus 로고    scopus 로고
    • Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
    • Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis. 2009;68:1146-52.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 1146-1152
    • Combe, B.1    Codreanu, C.2    Fiocco, U.3    Gaubitz, M.4    Geusens, P.P.5    Kvien, T.K.6
  • 169
    • 10744223002 scopus 로고    scopus 로고
    • Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
    • Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675-81.
    • (2004) Lancet. , vol.363 , pp. 675-681
    • Klareskog, L.1    Van Der Heijde, D.2    De Jager, J.P.3    Gough, A.4    Kalden, J.5    Malaise, M.6
  • 170
    • 38749088727 scopus 로고    scopus 로고
    • The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy
    • van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Mola EM, Pedersen R, et al. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Ann Rheum Dis. 2008;67:182-8.
    • (2008) Ann Rheum Dis. , vol.67 , pp. 182-188
    • van der Heijde, D.1    Burmester, G.2    Melo-Gomes, J.3    Codreanu, C.4    Mola, E.M.5    Pedersen, R.6
  • 171
    • 53149141023 scopus 로고    scopus 로고
    • Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate
    • Kavanaugh A, Klareskog L, van der Heijde D, Li J, Freundlich B, Hooper M. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis. 2008;67:1444-7.
    • (2008) Ann Rheum Dis. , vol.67 , pp. 1444-1447
    • Kavanaugh, A.1    Klareskog, L.2    van der Heijde, D.3    Li, J.4    Freundlich, B.5    Hooper, M.6
  • 172
    • 33751268255 scopus 로고    scopus 로고
    • A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs
    • Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis. 2006;65:1578-84.
    • (2006) Ann Rheum Dis. , vol.65 , pp. 1578-1584
    • Klareskog, L.1    Gaubitz, M.2    Rodriguez-Valverde, V.3    Malaise, M.4    Dougados, M.5    Wajdula, J.6
  • 173
    • 79959516247 scopus 로고    scopus 로고
    • Assessment of long-termsafety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis
    • Klareskog L, Gaubitz M, Rodríguez-Valverde V, Malaise M, Dougados M, Wajdula J. Assessment of long-termsafety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2011;29:238-47.
    • (2011) Clin Exp Rheumatol. , vol.29 , pp. 238-247
    • Klareskog, L.1    Gaubitz, M.2    Rodríguez-Valverde, V.3    Malaise, M.4    Dougados, M.5    Wajdula, J.6
  • 175
    • 47249094097 scopus 로고    scopus 로고
    • Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study
    • Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO 3rd, Li J, Louie J, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum. 2008;58:1921-30.
    • (2008) Arthritis Rheum. , vol.58 , pp. 1921-1930
    • Weinblatt, M.E.1    Schiff, M.H.2    Ruderman, E.M.3    Bingham, L.4    Louie, J.5
  • 176
    • 33646379583 scopus 로고    scopus 로고
    • The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial
    • Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54:1075-86.
    • (2006) Arthritis Rheum. , vol.54 , pp. 1075-1086
    • Westhovens, R.1    Yocum, D.2    Han, J.3    Berman, A.4    Strusberg, I.5    Geusens, P.6
  • 177
    • 8444239359 scopus 로고    scopus 로고
    • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial
    • St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-43.
    • (2004) Arthritis Rheum. , vol.50 , pp. 3432-3443
    • St Clair, E.W.1    van der Heijde, D.M.2    Smolen, J.S.3    Maini, R.N.4    Bathon, J.M.5    Emery, P.6
  • 178
    • 79955554422 scopus 로고    scopus 로고
    • The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy
    • Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum. 2011;63:1200-10.
    • (2011) Arthritis Rheum. , vol.63 , pp. 1200-1210
    • Emery, P.1    Fleischmann, R.2    van der Heijde, D.3    Keystone, E.C.4    Genovese, M.C.5    Conaghan, P.G.6
  • 179
    • 67449133560 scopus 로고    scopus 로고
    • Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
    • Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68:789-96.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 789-796
    • Keystone, E.C.1    Genovese, M.C.2    Klareskog, L.3    Hsia, E.C.4    Hall, S.T.5    Miranda, P.C.6
  • 180
    • 77950523739 scopus 로고    scopus 로고
    • Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study
    • Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010;62:917-28.
    • (2010) Arthritis Rheum. , vol.62 , pp. 917-928
    • Kremer, J.1    Ritchlin, C.2    Mendelsohn, A.3    Baker, D.4    Kim, L.5    Xu, Z.6
  • 181
    • 42449157502 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo controlled, dose-ranging study
    • Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo controlled, dose-ranging study. Arthritis Rheum. 2008;58:964-75.
    • (2008) Arthritis Rheum. , vol.58 , pp. 964-975
    • Kay, J.1    Matteson, E.L.2    Dasgupta, B.3    Nash, P.4    Durez, P.5    Hall, S.6
  • 183
    • 79953718761 scopus 로고    scopus 로고
    • Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial
    • Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum. 2011;63:622-32.
    • (2011) Arthritis Rheum. , vol.63 , pp. 622-632
    • Greenwald, M.W.1    Shergy, W.J.2    Kaine, J.L.3    Sweetser, M.T.4    Gilder, K.5    Linnik, M.D.6
  • 184
    • 78650645377 scopus 로고    scopus 로고
    • Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
    • Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, StohW, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46.
    • (2011) Ann Rheum Dis. , vol.70 , pp. 39-46
    • Tak, P.P.1    Rigby, W.F.2    Rubbert-Roth, A.3    Peterfy, C.G.4    van Vollenhoven, R.F.5    Stoh, W.6
  • 185
    • 77955738274 scopus 로고    scopus 로고
    • Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
    • Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, Armstrong G, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683-93.
    • (2010) Rheumatology (Oxford). , vol.49 , pp. 1683-1693
    • Rubbert-Roth, A.1    Tak, P.P.2    Zerbini, C.3    Tremblay, J.L.4    Carreño, L.5    Armstrong, G.6
  • 186
    • 45349086988 scopus 로고    scopus 로고
    • Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy
    • Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2008;59:785-93.
    • (2008) Arthritis Rheum. , vol.59 , pp. 785-793
    • Keystone, E.1    Burmester, G.R.2    Furie, R.3    Loveless, J.E.4    Emery, P.5    Kremer, J.6
  • 187
    • 33751414085 scopus 로고    scopus 로고
    • Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years
    • Strand V, Balbir-Gurman A, Pavelka K, Emery P, Li N, Yin M, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology (Oxford). 2006;45: 1505-13.
    • (2006) Rheumatology (Oxford). , vol.45 , pp. 1505-1513
    • Strand, V.1    Balbir-Gurman, A.2    Pavelka, K.3    Emery, P.4    Li, N.5    Yin, M.6
  • 188
    • 33646483031 scopus 로고    scopus 로고
    • The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase II B randomized, double-blind, placebo-controlled, dose-ranging trial
    • Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase II B randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-400.
    • (2006) Arthritis Rheum. , vol.54 , pp. 1390-1400
    • Emery, P.1    Fleischmann, R.2    Filipowicz-Sosnowska, A.3    Schechtman, J.4    Szczepanski, L.5    Kavanaugh, A.6
  • 190
    • 79953680176 scopus 로고    scopus 로고
    • Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year
    • Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63:609-21.
    • (2011) Arthritis Rheum. , vol.63 , pp. 609-621
    • Kremer, J.M.1    Blanco, R.2    Brzosko, M.3    Burgos-Vargas, R.4    Halland, A.M.5    Vernon, E.6
  • 191
    • 79951942809 scopus 로고    scopus 로고
    • Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study
    • Hashimoto J, Garnero P, van der HeijdeD, Miyasaka N, Yamamoto K, Kawai S, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol. 2011;21:10-5.
    • (2011) Mod Rheumatol. , vol.21 , pp. 10-15
    • Hashimoto, J.1    Garnero, P.2    van der Heijde, D.3    Miyasaka, N.4    Yamamoto, K.5    Kawai, S.6
  • 192
    • 54949150604 scopus 로고    scopus 로고
    • Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
    • Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968-80.
    • (2008) Arthritis Rheum. , vol.58 , pp. 2968-2980
    • Genovese, M.C.1    McKay, J.D.2    Nasonov, E.L.3    Mysler, E.F.4    Da Silva, N.A.5    Alecock, E.6
  • 193
    • 40749114497 scopus 로고    scopus 로고
    • Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): adoubleblind, placebo-controlled, randomized trial
    • Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): adoubleblind, placebo-controlled, randomized trial. Lancet. 2008;371:987-97.
    • (2008) Lancet. , vol.371 , pp. 987-997
    • Smolen, J.S.1    Beaulieu, A.2    Rubbert-Roth, A.3    Ramos-Remus, C.4    Rovensky, J.5    Alecock, E.6
  • 194
    • 79952264014 scopus 로고    scopus 로고
    • The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials
    • Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scand J Rheumatol. 2011;40:1-7.
    • (2011) Scand J Rheumatol. , vol.40 , pp. 1-7
    • Kristensen, L.E.1    Jakobsen, A.K.2    Bartels, E.M.3    Geborek, P.4    Bliddal, H.5    Saxne, T.6
  • 195
    • 47949106400 scopus 로고    scopus 로고
    • Efficacy and safety of abataceptor infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebocontrolled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
    • Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abataceptor infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebocontrolled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67: 1096-103.
    • (2008) Ann Rheum Dis. , vol.67 , pp. 1096-1103
    • Schiff, M.1    Keiserman, M.2    Codding, C.3    Songcharoen, S.4    Berman, A.5    Nayiager, S.6
  • 196
    • 24944498854 scopus 로고    scopus 로고
    • Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
    • Genovese MC, Becker JC, Schiff M, LuggenM, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114-23.
    • (2005) N Engl J Med. , vol.353 , pp. 1114-1123
    • Genovese, M.C.1    Becker, J.C.2    Schiff, M.3    Luggen, M.4    Sherrer, Y.5    Kremer, J.6
  • 197
    • 41849120516 scopus 로고    scopus 로고
    • Efficacy and safety of the selective costimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
    • Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, et al. Efficacy and safety of the selective costimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67:547-54.
    • (2008) Ann Rheum Dis. , vol.67 , pp. 547-554
    • Genovese, M.C.1    Schiff, M.2    Luggen, M.3    Becker, J.C.4    Aranda, R.5    Teng, J.6
  • 198
    • 33745291091 scopus 로고    scopus 로고
    • Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial
    • Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865-76.
    • (2006) Ann Intern Med. , vol.144 , pp. 865-876
    • Kremer, J.M.1    Genant, H.K.2    Moreland, L.W.3    Russell, A.S.4    Emery, P.5    Abud-Mendoza, C.6
  • 199
    • 42449098374 scopus 로고    scopus 로고
    • Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate
    • Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008;58:953-63.
    • (2008) Arthritis Rheum. , vol.58 , pp. 953-963
    • Kremer, J.M.1    Genant, H.K.2    Moreland, L.W.3    Russell, A.S.4    Emery, P.5    Abud-Mendoza, C.6
  • 202
    • 0035003318 scopus 로고    scopus 로고
    • Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area
    • Hamilton J, McInnes IB, Thomson EA, Porter D, Hunter JA, Madhok R, et al. Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Ann Rheum Dis. 2001;60: 566-72.
    • (2001) Ann Rheum Dis. , vol.60 , pp. 566-572
    • Hamilton, J.1    McInnes, I.B.2    Thomson, E.A.3    Porter, D.4    Hunter, J.A.5    Madhok, R.6
  • 206
    • 78751704593 scopus 로고    scopus 로고
    • Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumournecrosis factor agent: a meta-analysis
    • Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumournecrosis factor agent: a meta-analysis. Ann Rheum Dis. 2011;70:266-71.
    • (2011) Ann Rheum Dis. , vol.70 , pp. 266-271
    • Salliot, C.1    Finckh, A.2    Katchamart, W.3    Lu, Y.4    Sun, Y.5    Bombardier, C.6
  • 207
    • 79956333690 scopus 로고    scopus 로고
    • Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
    • Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15:1-278.
    • (2011) Health Technol Assess. , vol.15 , pp. 1-278
    • Malottki, K.1    Barton, P.2    Tsourapas, A.3    Uthman, A.O.4    Liu, Z.5    Routh, K.6
  • 208
    • 77957265767 scopus 로고    scopus 로고
    • Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis
    • O'Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2010;69:1823-6.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 1823-1826
    • O'Mahony, R.1    Richards, A.2    Deighton, C.3    Scott, D.4
  • 209
    • 3242677099 scopus 로고    scopus 로고
    • Effect of a treatment strategy of tight controlforrheumatoid arthritis (the TICORAstudy): a singleblindrandomised controlledtrial
    • Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight controlforrheumatoid arthritis (the TICORAstudy): a singleblindrandomised controlledtrial. Lancet. 2004;364:263-69.
    • (2004) Lancet. , vol.364 , pp. 263-269
    • Grigor, C.1    Capell, H.2    Stirling, A.3    McMahon, A.D.4    Lock, P.5    Vallance, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.